Pharma Marketing News
PMN Home | Advertising Information | FAQs
About Us | Contact Us | Privacy Policy
Subscribe Glossary
Pharma Marketing Blog Pharmaguy Audio Podcasts Event Calendar PReader Surveys

Share |

Reforming the FDA
It All Starts with a New Commissioner! NOT!

Shiny New FDA"[The Committee on Energy and Commerce in the US House and Representatives] has found that FDA not only failed in its basic mission, but refused to admit its failures and take steps to protect Americans from unsafe food and drugs," said Rep. John D. Dingell (D-MI), former chairman of that committee. "In the 111th Congress, the committee will swiftly move FDA reform legislation that is needed to ensure FDA does its job." Now that Henry Waxman is the new chairman, "swift" may be inadequate to describe the changes ahead for the FDA.

The biggest and possibly most important change, however, is who President-elect Obama and his Secretary of HHS, Tom Daschle, decide to nominate for the new FDA Commissioner.

It seems like everyone in the Pharma Blogosphere and the press is recommending or wondering who Dr. Andrew von Eschenbach's replacement will be.

To help take the pulse of various stakeholders, Pharma Marketing News hosted the "Who Should Obama Nominate for FDA Commissioner?" survey starting in November, 2008. 475 consumers, healthcare professionals, government agency staffers, and drug industry executives have voted in this survey. This article summarizes the results.

Topic headings include:

  • Obama In, Eschenbach Out!
  • The Pundits Weigh In
  • The Candidates
  • Profile of Respondents
  • And the Winner Is...
  • Peter Rost - A Special Case 
  • Who Voted for Whom?
  • Comments from Voters and Candidates

Read this article now. It's FREE...

Download PDF file

Update (December, 2011): Replacing the FDA Commissioner may have been a necessary, but NOT SUFFICIENT pre-requisite for reforming the FDA. Not even a reform-minded commissioner like Margaret Hamburg, M.D. -- who was nominated to the post after this article was first published -- can change things when the FDA is beholding to the Department of Health and Human Services. This was made evident when HHS Secretary Kathleen Sebelius over-rode FDA's decision to allow the over-the-couinter sale of Plan B One-Step to girls younger than 17 (see "Sebelius vs. Hamburg on OTC Plan B Decision").

Meanwhile, there is a new call for FDA reform that would take the F.D.A. out of the Department of Health and Human Services and make it an independent agency, like the Fed (op cit).

Issue: Vol. 7, No. 10: December 2008
Word Count: 5868

Find other articles in related Topic Areas:

Vol 7, #10 Contents

Contact Information
Pharma Marketing News

Pharma Marketing News | Subscribe | Industry Insights | Podcasts | Pharmaguy | Blog
Surveys | Glossary | Conference Calendar | Advertising Information | FAQs | About Us | Privacy Policy

© 2014. Pharma Marketing Network. All rights reserved.